Compare AFLAC Incorporated (AFL) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AFLAC Incorporated vs BioNTech SE - ADR — how do they compare? AFLAC Incorporated trades at $121.31 (market cap $60.70B), while BioNTech SE - ADR trades at $93.53 (market cap $23.31B). The key difference: AFLAC Incorporated is far larger — about 2.6× BioNTech SE - ADR's market cap, and AFLAC Incorporated pays a 2.02% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| AFL | BNTX | |
|---|---|---|
Market Cap | $60.70B | $23.31B |
Sector | Financials | Health |
52-Week High | $129.55 | $119.34 |
52-Week Low | $103.55 | $83.89 |
Enterprise Value | $70.65B | $6.60B |
Dividend Yield | 2.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AFL trades at $121.94, down 2.14% with bearish technical signals and recent earnings misses. The stock shows strong profitability with 26.59% net margin and 16.91% ROE, but faces revenue declines from $19.1B in 2024 to $17.4B in 2025. Recent news highlights AFL's rebranding efforts and dividend consistency amid healthcare cost pressures. Technical indicators show oversold RSI at 17.69 with support at $117.
Outlook remains cautious with mixed analyst sentiment (28% buy, 56% hold) and $118 consensus target below current price. Risks include Japan market exposure and currency headwinds, balanced by 43-year dividend growth history and strong cash flow generation. The stock offers value at 13x P/E but requires monitoring of revenue stabilization.
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
